Printer Friendly

IVAX RESPONDS TO COMPLAINT FILED REGARDING TRINITY CAPITAL ENTERPRISE TRANSACTION

 IVAX RESPONDS TO COMPLAINT FILED REGARDING
 TRINITY CAPITAL ENTERPRISE TRANSACTION
 MIAMI, March 26 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that it had received notice from Trinity Capital Enterprise Corp. (NASDAQ: TICO) that a lawsuit has been instituted against Trinity and certain of its officer and directors. The lawsuit alleges violation of Federal securities laws in connection with the Feb. 6, 1992 announcement of the proposed merger of two of IVAX' wholly owned subsidiaries, Diamedix Corporation and GDU Trading Company, Ltd., with Trinity. Subject to continuing review of the lawsuit, IVAX confirmed its intention to proceed with the merger as outlined in the February 6, 1992 press release.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Best Generics, Inc., a national distributor of off- patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 3/26/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX TICO) CO: IVAX Corporation; Trinity Capital Enterprise Corp. ST: Florida IN: MTC SU:


SS-AW -- FL011 -- 2071 03/26/92 15:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 26, 1992
Words:271
Previous Article:FIRST CHICAGO TO REDEEM NOTES
Next Article:AMERICAN AIRCRAFT AND CYCLONE AVIATION'S JOINT VENTURE LAUNCHED
Topics:


Related Articles
IVAX ENTERS INTO AGREEMENT TO ACQUIRE WILLEN DRUG COMPANY
IVAX AGREES TO CEASE SALE OF LOOK-ALIKE GENERIC
IVAX CORPORATION AND TRINITY CAPITAL ENTERPRISE CORP. AGREE TO TERMINATE PROPOSED TRANSACTION
PHILLIP FROST FILES HART-SCOTT-RODINO NOTICE RELATING TO POSSIBLE ACQUISITION OF IVAX SHARES
IVAX COMMENTS ON LAWSUIT FILED BY JAMES SWEENEY
IVAX COMMENTS ON PATENT SUIT FILED BY ELI LILLY
IVAX CORPORATION RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC TERFENADINE
IVAX' NDA FOR ELMIRON DECLARED APPROVABLE BY FDA
FDA Confirms First Filed Paclitaxel Injection Application
Alpharma Settles Gabapentin Exclusivity Litigation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters